Literature DB >> 17932208

Epilepsy in pregnancy.

Torbjörn Tomson1, Vilho Hiilesmaa.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17932208      PMCID: PMC2018809          DOI: 10.1136/bmj.39266.473113.BE

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  44 in total

Review 1.  The significance of folic acid for epilepsy patients.

Authors:  James Layne Moore
Journal:  Epilepsy Behav       Date:  2005-09       Impact factor: 2.937

2.  Individual changes in lamotrigine plasma concentrations during pregnancy.

Authors:  Vaiva Petrenaite; Anne Sabers; Jacob Hansen-Schwartz
Journal:  Epilepsy Res       Date:  2005-07       Impact factor: 3.045

Review 3.  Teratogenicity of antiepileptic drugs: state of the art.

Authors:  Torbjörn Tomson; Dina Battino
Journal:  Curr Opin Neurol       Date:  2005-04       Impact factor: 5.710

4.  Antiepileptic drug use of women with epilepsy and congenital malformations in offspring.

Authors:  M Artama; A Auvinen; T Raudaskoski; I Isojärvi; J Isojärvi
Journal:  Neurology       Date:  2005-06-14       Impact factor: 9.910

5.  Increased rate of major malformations in offspring exposed to valproate during pregnancy.

Authors:  D F Wyszynski; M Nambisan; T Surve; R M Alsdorf; C R Smith; L B Holmes
Journal:  Neurology       Date:  2005-03-22       Impact factor: 9.910

6.  Neuropsychological effects of exposure to anticonvulsant medication in utero.

Authors:  J Vinten; N Adab; U Kini; J Gorry; J Gregg; G A Baker
Journal:  Neurology       Date:  2005-03-22       Impact factor: 9.910

7.  Pregnancy and epilepsy: a retrospective study of 151 pregnancies.

Authors:  A Sabers; B aRogvi-Hansen; M Dam; W Fischer-Rasmussen; L Gram; M Hansen; A Møller; H Winkel
Journal:  Acta Neurol Scand       Date:  1998-03       Impact factor: 3.209

8.  Children exposed to valproate in utero--population based evaluation of risks and confounding factors for long-term neurocognitive development.

Authors:  Kai Eriksson; Katriina Viinikainen; Anne Mönkkönen; Marja Aikiä; Pirkko Nieminen; Seppo Heinonen; Reetta Kälviäinen
Journal:  Epilepsy Res       Date:  2005-07       Impact factor: 3.045

9.  Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy.

Authors:  Frank J Vajda; Terence J O'brien; Alison Hitchcock; Janet Graham; Mark Cook; Cecilie Lander; Mervyn J Eadie
Journal:  J Clin Neurosci       Date:  2004-11       Impact factor: 1.961

10.  Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin.

Authors:  T Tomson; U Lindbom; B Ekqvist; A Sundqvist
Journal:  Epilepsia       Date:  1994 Jan-Feb       Impact factor: 5.864

View more
  5 in total

1.  Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004-2006.

Authors:  Anders Engeland; Jørgen G Bramness; Anne Kjersti Daltveit; Marit Rønning; Svetlana Skurtveit; Kari Furu
Journal:  Br J Clin Pharmacol       Date:  2008-02-20       Impact factor: 4.335

2.  No increase in adverse pregnancy outcomes for women receiving antiepileptic drugs.

Authors:  Hsiu-Li Lin; Yi-Hua Chen; Hsiu-Chen Lin; Herng-Ching Lin
Journal:  J Neurol       Date:  2009-06-30       Impact factor: 4.849

3.  Drug prescribing before and during pregnancy in south west France: a retrolective study.

Authors:  Sophie Crespin; Robert Bourrel; Caroline Hurault-Delarue; Maryse Lapeyre-Mestre; Jean-Louis Montastruc; Christine Damase-Michel
Journal:  Drug Saf       Date:  2011-07-01       Impact factor: 5.606

4.  Gilles de la Tourette syndrome in pregnancy: a retrospective series.

Authors:  J S Stern; M Orth; M M Robertson
Journal:  Obstet Med       Date:  2009-09-01

Review 5.  Pregnancy and epilepsy: what should we tell our patients?

Authors:  Torbjörn Tomson; Dina Battino
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.